Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928

Manufacturer: Mirum Pharmaceuticals
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in October 2026
Last updated: October 1, 2026

Section

Product information and disease description Product description

Product information

84 evidence topics · 28 sources

Generic, brand name and therapeutic class of product4 evidence topics · 3 sources
Dosage forms and strengths4 evidence topics · 2 sources
Average sales price and wholesale acquisition cost7 evidence topics · 6 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication3 evidence topics · 1 source
Pharmacology18 evidence topics · 5 sources
Contraindications/Warnings/Precautions/Adverse effects8 evidence topics · 2 sources
Special populations9 evidence topics · 2 sources
Drug/Drug, drug/disease interactions12 evidence topics · 2 sources
Dosing and administration5 evidence topics · 2 sources
Access and distribution4 evidence topics · 5 sources
Co-prescribed/Concomitant therapies2 evidence topics · 1 source
Product comparison7 evidence topics · 10 sources

Effect of zilurgisertib on quality measures

No evidence found.